Literature DB >> 20029945

Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse.

Anna Solovey1, Rahn Kollander, Liming Chang Milbauer, Fuad Abdulla, Yingie Chen, Robert J Kelm, Robert P Hebbel.   

Abstract

Activation of the coagulation system is a characteristic feature of sickle cell anemia, which also includes clinical thrombosis. The sickle transgenic mouse abnormally expresses tissue factor (TF) on the pulmonary vein endothelium. Knowing that this aberrancy is stimulated by inflammation, we sought to determine whether nitric oxide (NO) contributes to regulation of endothelial TF expression in the sickle mouse model. We used the NY1DD sickle mouse, which exhibits a low-TF to high-TF phenotype switch on exposure to hypoxia/reoxygenation. Manipulations of NO biology, such as breathing NO or addition of arginine or L-NAME (N-nitro-L-arginine-methyl-ester) to the diet, caused significant modulations of TF expression. This was also seen in hBERK1 sickle mice, which have a different genetic background and already have high-TF even at ambient air. Study of NY1DD animals bred to overexpress endothelial nitric oxide synthase (eNOS; eNOS-Tg) or to have an eNOS knockout state (one eNOS(-/-) animal and several eNOS(+/-) animals) demonstrated that eNOS modulates endothelial TF expression in vivo by down-regulating it. Thus, the biodeficiency of NO characteristic of patients with sickle cell anemia may heighten risk for activation of the coagulation system. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20029945     DOI: 10.1002/ajh.21582

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  Role of reactive oxygen and nitrogen species in the vascular responses to inflammation.

Authors:  Peter R Kvietys; D Neil Granger
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

Review 2.  Tissue factor and thrombin in sickle cell anemia.

Authors:  Pichika Chantrathammachart; Rafal Pawlinski
Journal:  Thromb Res       Date:  2012-03-06       Impact factor: 3.944

3.  Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell disease.

Authors:  Ashley T Freeman; Kenneth I Ataga
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

4.  A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.

Authors:  Carolyn Hoppe; Frans Kuypers; Sandra Larkin; Ward Hagar; Elliott Vichinsky; Lori Styles
Journal:  Br J Haematol       Date:  2011-04-08       Impact factor: 6.998

5.  Plasma metabolomic profiles in different stages of CKD.

Authors:  Vallabh O Shah; Raymond R Townsend; Harold I Feldman; Kirk L Pappan; Elizabeth Kensicki; David L Vander Jagt
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

6.  The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.

Authors:  Robert P Hebbel; Gregory M Vercellotti; Betty S Pace; Anna N Solovey; Rahn Kollander; Chine F Abanonu; Julia Nguyen; Julie V Vineyard; John D Belcher; Fuad Abdulla; Shadé Osifuye; John W Eaton; Robert J Kelm; Arne Slungaard
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

Review 7.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 8.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

9.  A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis.

Authors:  Robert P Hebbel; Greg Vercellotti; Karl A Nath
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2009-12

10.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.